Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Child Pugh Score

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    181 result(s) found for: Child Pugh Score. Displaying page 1 of 10.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2021-001235-12 Sponsor Protocol Number: GULLIVER-2 Start Date*: 2021-07-20
    Sponsor Name:Galecto Biotech AB
    Full Title: GULLIVER-2 - a single (open-label) and repeat dose (randomised, placebo-controlled) trial to assess the safety, tolerability and pharmacokinetics of GB1211 (Gal-3 inhibitor) in participants with he...
    Medical condition: Healthy subjects (for study Parts 1 and 3) and patients with hepatic impairment (Child Pugh B and Child Pugh C) (cirrhosis)
    Disease: Version SOC Term Classification Code Term Level
    22.1 100000004871 10052254 Hepatic impairment LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2015-002567-42 Sponsor Protocol Number: 5A Start Date*: 2015-07-15
    Sponsor Name:Stockholm County Council, Karolinska University Hospital Huddinge, Dept of Anesthesiology and Intensive Care
    Full Title: Predictors of albumin synthesis rate in severe liver failure. An open exploratory study in patients with chronic liver failure assessed for liver transplantation
    Medical condition: Severe chronic liver failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-002079-16 Sponsor Protocol Number: E2013_PK_CASPO70_LIVERFAILURE Start Date*: 2013-09-05
    Sponsor Name:Hospital Erasme
    Full Title: Pharmacokinetics of Caspofungin after one dose in patients with liver failure.
    Medical condition: The pharmacokinetics parameters of caspofungin will be studied for the patient admitted for alcoholic hepatitis or decompensated cirrhosis (Child-Pugh score 7-15).
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004871 10024678 Liver failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-015785-64 Sponsor Protocol Number: PRODIGE 11/FFCD 0803 Start Date*: 2009-11-17
    Sponsor Name:CHU de DIJON - Délégation à la recherche clinique et à l’innovation
    Full Title: ESSAI RANDOMISE - SORAFENIB-PRAVASTATINE VERSUS SORAFENIB SEUL POUR LE TRAITEMENT PALLIATIF DU CARCINOME HEPATOCELLULAIRE CHILD-PUGH A
    Medical condition: Carcinome hépatocellulaire (CHC) non accessible à un traitement à visée curative
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-004371-22 Sponsor Protocol Number: ADN009 Start Date*: 2015-01-12
    Sponsor Name:ADIENNE SA
    Full Title: Phase IV study to assess, the effect of hepatic impairment on the pharmacokinetics of Thiotepa and the potential of Thiotepa to alter the QT interval in pedatric patients undergoing allogeneic haem...
    Medical condition: Patients with various hematological disease requiring Bone Marrow Transplantation, with Child-Pugh score A and B
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004865 10067859 Allogenic stem cell transplantation LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-008232-87 Sponsor Protocol Number: SOCS-B Start Date*: 2009-04-03
    Sponsor Name:Charite Universitätsmedizin Berlin- Campus Virchow-Klinikum
    Full Title: Open-label phase II study of sorafenib in patients with advanced hepatocellular carcinoma (HCC) and Child Pugh score B with special analysis of patients 65 years or older
    Medical condition: hepatocellular carcinoma and Child Pugh score B
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-004031-23 Sponsor Protocol Number: E2012AILIVER Start Date*: 2014-08-26
    Sponsor Name:Hopital Erasme
    Full Title: Serum pharmacokinetics of Caspofungin in patients with liver failure.
    Medical condition: The patient admitted for alcoholic hepatitis or decompensated cirrhosis (Child-Pugh score of 10-15) presenting with invasive aspergillosis (proven or probable) and treated by caspofungin.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004871 10024678 Liver failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003108-15 Sponsor Protocol Number: UC-GIG-2003 Start Date*: 2022-11-04
    Sponsor Name:UNICANCER
    Full Title: A multicentric national phase II trial assessing TIslelizumab in monotherapy for patients with Hepatocellular Carcinoma Child-Pugh B and ALBI grade 1 or 2 liver function Score
    Medical condition: Hepatocellular Carcinoma (HCC), Child-Pugh B, ALBI grade 1 or 2 liver function
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073069 Hepatic cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-001139-22 Sponsor Protocol Number: POPH Start Date*: 2011-06-29
    Sponsor Name:Medizinische Universität Graz, Klin. Abteilung für Gastroenterologie und Hepatologie
    Full Title: AMBRISENTAN FOR TREATMENT OF PORTOPULMONARY HYPERTENSION (POPH): A PILOT STUDY
    Medical condition: Portopulmonary Hypertension (PoPH) and Hepatopulmonary Syndrome HPS are present in a considerable number of patients with compensated cirrhosis. Treatment of PoPH with ambrisentan is well tolerated...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10067281 Portopulmonary hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-021590-37 Sponsor Protocol Number: A4061058 Start Date*: 2011-01-03
    Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY10017,USA
    Full Title: A MULTICENTER, GLOBAL, RANDOMIZED, DOUBLE-BLIND STUDY OF AXITINIB PLUS BEST SUPPORTIVE CARE VERSUS PLACEBO PLUS BEST SUPPORTIVE CARE IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA FOLLOWING FAI...
    Medical condition: Hepatocellular carcinoma (HCC)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019829 Hepatocellular carcinoma recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) SK (Completed) GB (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-002088-25 Sponsor Protocol Number: N-003-CRD003 Start Date*: 2019-01-11
    Sponsor Name:Noorik Biopharmaceuticals AG
    Full Title: A Phase II, Single-arm, Open-Label Study to Characterise the Effect on Portal Pressure, the Effect on Renal Function and the Pharmacokinetic Profile of N-003 in Patients with Decompensated Cirrhosis
    Medical condition: decompensated liver cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004871 10064704 Decompensated cirrhosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-002053-30 Sponsor Protocol Number: EMR200095-005 Start Date*: 2014-05-16
    Sponsor Name:Merck KGaA
    Full Title: A Multicenter, Single Arm, Phase Ib/II Study to Evaluate Efficacy, Safety, and PK of MSC2156119J as Monotherapy in Subjects with MET+ Advanced Hepatocellular Carcinoma with Child Pugh Class A Liv...
    Medical condition: Hepatocellular Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-011925-14 Sponsor Protocol Number: 1199.37 Start Date*: 2009-08-24
    Sponsor Name:Boehringer Ingelheim
    Full Title: A multicenter, open label, phase I / II study to evaluate safety, pharmacokinetics and efficacy of BIBF 1120 in comparison with oral sorafenib for advanced hepatocellular carcinoma patients.
    Medical condition: Histologically or cytologically confirmed hepatocellular carcinoma not amenable to local therapy with adequate renal, hematological and liver paramenters with Child-Pugh score 7 or less, in 1st lin...
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10049010 Carcinoma hepatocellular LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) AT (Completed) DE (Completed) SK (Completed) HU (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2010-019318-26 Sponsor Protocol Number: IMCL_CP12-0919_(I4T-IE-JVBF) Start Date*: 2010-09-27
    Sponsor Name:ImClone LLC
    Full Title: A Multicenter, Randomized, Double-Blind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepato...
    Medical condition: Hepatocellular Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) DE (Completed) CZ (Completed) PT (Completed) BE (Completed) ES (Completed) AT (Completed) FR (Completed) BG (Completed) HU (Completed) IT (Completed) SE (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2019-001075-36 Sponsor Protocol Number: CaboCHILD Start Date*: 2020-04-20
    Sponsor Name:Universitätsmedizin Mainz
    Full Title: A phase II study to evaluate the safety, tolerability and efficacy of Cabozantinib in patients with hepatocellular carcinoma (HCC) and impaired liver function (Child-Pugh score B7-8) - CABOCHILD -
    Medical condition: Hepatocellular carcinoma (HCC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-004728-39 Sponsor Protocol Number: AURORA Start Date*: 2020-07-31
    Sponsor Name:Frankfurter Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest
    Full Title: A Phase II, non-randomized, single arm, translational study of CAbozantinib for Patients with HepatocellUlaR CarcinOma (HCC) Refractory to first line TreAtment
    Medical condition: Locally advanced or metastatic and/or unresectable HCC
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000680-74 Sponsor Protocol Number: IC/LV/ACZ/PCHC Start Date*: 2021-08-26
    Sponsor Name:Laboratorios Viñas, S.A.
    Full Title: Multicenter, randomized, double-blind, comparative clinical trial to assess the efficacy of Zinc Acexamate (ACZ) versus placebo in the prevention of events in patients with compensated liver cirrhosis
    Medical condition: Compensated cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004871 10064844 Compensated cirrhosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-003925-17 Sponsor Protocol Number: HCC-PBMC-GM-CSF Start Date*: 2008-10-20
    Sponsor Name:AZIENDA OSPEDALIERA DI PARMA
    Full Title: Immunotherapy by autologous peripheral blood mononuclear cells and GM-CSF for hepatocellular carcinoma undergoing radiofrequency thermal ablation
    Medical condition: patients with hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059319 Hepatic cancer stage II LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-003557-27 Sponsor Protocol Number: SA-388-4-1 Start Date*: Information not available in EudraCT
    Sponsor Name:Dean of the Medical Faculty (University of Bonn)
    Full Title: Covered Transjugular Intrahepatic Portosystemic Stent Shunt versus Optimized medical Treatment for the Secondary Prevention of Variceal Bleeding in Cirrhosis
    Medical condition: liver cirrhosis; esophageal (variceal) bleeding
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-003972-23 Sponsor Protocol Number: hcc1 Start Date*: 2009-01-09
    Sponsor Name:LUMC
    Full Title: Hepatocellular carcinoma: vascular abnormalities prior to, during and following systemic anti-cancer treatment
    Medical condition: The primary objective of this study is to determine the efficacy of the combination of everolimus and capecitabine in a group of patients with metastatic or locally advanced HCC. In addition, to in...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019828 Hepatocellular carcinoma non-resectable LLT
    9.1 10019829 Hepatocellular carcinoma recurrent LLT
    9.1 10008452 Chemotherapy multiple agents systemic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 21:44:57 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA